Orchard Therapeutics PLC
Simon Briggs has a diverse background in the biopharmaceutical industry, with a focus on advanced analytics and technical development. Simon held roles at companies such as Orchard Therapeutics, Biogen, Novartis, and UCB Pharma, where they led teams in process development, analytics, and product stewardship. Simon's experience spans gene therapy, biologics manufacturing, and cell therapy, showcasing their expertise in regulatory support, process analytics, and late-phase development. Their work history includes positions like Director of Advanced Analytics, Head of Gene Therapy Technical Product Development, and Group Leader in Process Analytics.
Simon Briggs completed a BSc Hons in Biotechnology and Chemistry at the University of Plymouth from 1997 to 2000. Simon went on to earn their PhD in Chemistry from the University of Birmingham between 2000 and 2004.
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.